Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma
Open Access
- 29 October 2024
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-6
Abstract
Objectives: To investigate the impact of TFE3 rearrangement, analyzing clinicopathological features that influence renal cell carcinoma (RCC) recurrence, and clarify the role of immunohistochemistry (IHC) staining in diagnosis. Methods: We screened patients diagnosed of clear cell RCC (ccRCC), fluorescence in situ hybridization (FISH) was performed on all TFE3 positive IHC tumors. Clinicopathological and survival features were collected for analysis. Results: Out of 695 patients treated for renal tumors, 478 (68.7%) were ccRCC and 22 were suspected of TFE3 rearrangement based on IHC. Subsequent testing revealed 8 (1.15%) were positive in the FISH test (TFE3-rearranged-RCC) and 14 (2.01%) tested negative. No significant differences were noted in general characteristics among the three groups, except for age, TFE3-rearranged-RCC were younger than ccRCC (median age, 49 vs. 58 years, p = 0.02). TFE3-rearranged-RCC exhibited a significant higher recurrence rate compared to ccRCC (50% vs 18.8%) and multivariate analysis revealed that TFE3 rearrangement, along with tumor size and metastasis, was an independent prognostic factor for recurrence (HR = 4.6; 95% CI 1.1-21.2; p = 0.05). Survival analysis demonstrated a significant shorter PFS (progression-free survival) for TFE3-rearranged-RCC compared to ccRCC. Conclusions: TFE3 rearrangement is an independent prognostic factor for recurrence and contributes to a worse PFS, suggesting the necessity of careful follow-up. Diagnosis should be confirmed using FISH due to low specificity of IHC. Further studies are needed to confirm TFE3 IHC staining as a prognostic factor.Keywords
Funding Information
- Universidad de Navarra
This publication has 18 references indexed in Scilit:
- Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrationsAmerican Journal of Clinical Pathology, 2023
- TFE3 gene rearrangement and protein expression contribute to a poor prognosis of renal cell carcinomaHeliyon, 2023
- The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular TumoursEuropean Urology, 2022
- Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international surveyJournal of Clinical Pathology, 2021
- Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusionBMC Cancer, 2019
- NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinomaLaboratory Investigation, 2019
- MiT family translocation renal cell carcinomaSeminars in Diagnostic Pathology, 2015
- MiT translocation renal cell carcinomas: two subgroups of tumours with translocations involving 6p21 [t (6; 11)] and Xp11.2 [t (X;1 or X or 17)]SpringerPlus, 2014
- Utilization of a TFE3 Break-apart FISH Assay in a Renal Tumor Consultation ServiceAmerican Journal of Surgical Pathology, 2013
- TFE3 Rearrangements in Adult Renal Cell CarcinomaAmerican Journal of Surgical Pathology, 2012